Table 3.
Related-references about IC plus CCRT in LA-NPC.
| Author | Year | Study design | Patients | Groups | Result | median follow-up | IC regime |
|---|---|---|---|---|---|---|---|
| Sun | 20167 | Prospective3 | stage III-IVB (except T3-4N0) | IC+CCRT vs CCRT | 3-year FFS 80% vs 72%,p = .034 | 45months | TPF |
| Frikha | 201821 | Prospective3 | stage III-IVB (except T3-4N0) |
IC+CCRT vs CCRT | 3-year PFS 73.9% vs 57.2%, P = .042 3-years OS 86.3% vs 68.9% P = .05 |
43.1months | TPF |
| Hong | 201822 | Prospective3 | stage IVA-IVB | IC+CCRT vs CCRT | 5-year DFS 61% vs 50%, P = .0264 | 72months | MEPFL |
| Li | 201917 | Prospective3 | stage III-IVB (except T3-4N0) |
IC+CCRT vs CCRT | 5-year FFS 77.4% vs. 66.4%, p = .019 5-yearOS 85.6% vs. 77.7%, p = .042 5-year DFFS 88% vs. 79.8%, p = .030 5-yearLFFS 90.7% vs. 83.8%, p = .044 |
71.5 months | TPF |
| Yang | 201923 | Prospective3 | stage III-IVB (except T3N0–1) |
IC+CCRT vs CCRT | 5-year DFS 73.4% vs 63.1%, p = .007 5-year DMFS 82.8% vs 73.1%, p = .014 5-year OS 80.8% vs 76.8%, p = .040 |
82.6 months | PF |
| Zhang | 202224 | Prospective3 | stage III-IVB (except T3-4N0) |
IC+CCRT vs CCRT | 5-year OS 87.9% vs 78.8%, P = .001 | 69.8months | GP |